

24th extraordinary meeting of the IMI2 Governing Board held on 12.12.2018 by audio-conference

Minutes

In accordance with Articles 4.4 and 4.8 of the IMI2 JU Governing Board Rules of Procedure ("the Rules of Procedure"), an extraordinary Board meeting was called on 12 December 2018 and held by audio conference.

The quorum was met pursuant to Article 7 of the Rules (Annex II) and the agenda approved (Annex I).

No potential or manifest conflict of interest was declared by any of the Governing Board Members.

The Governing Board adopted the IMI2 JU Annual Work Plan and Budget for 2019, together with a revised Manual for submission, evaluation and grant award, as proposed by the


The Commission urged the IMI Office to communicate the contents of the new Annual Work Plan immediately upon its adoption by the Governing Board.

Following a brief discussion regarding the evaluation thresholds, the Executive Director confirmed the IMI2 JU had begun assessing the relevance of the current scoring thresholds, and that it would report to the GB on this topic in April 2019.

The Decision adopted by the IMI2 JU Governing Board is in Annex III.

Done in Brussels on January 21, 2019

For the Governing Board of the Innovative Medicines Initiative 2 JU,





Annex I

24th Meeting of the IMI2 Governing Board - extraordinary

Agenda

12.12.2018 • 14:00-15:00 Brussels time • by audio-conference •

Welcome and Introduction

1 Adoption of the Agenda and declarations of interests with regard to agenda

Sole item for decision

2 IMI2 JU Annual Work Plan and Budget for 2019, together with a revised Manual for submission, evaluation and grant award: for adoption



Annex II

24th extraordinary meeting of the IMI2 Governing Board held on 12.12.2018 • 14:00–15:00 CET • by audio-conference •

Attendance

EFPIA attended UCB. Johnson & Johnson attended attended Novartis. **EFPIA** attended Enyo Pharma SA apologies Alternate members attended Pfizer IMI Office apologies External R&D Innovation European Commission Deputy Chair of the IMI2 Governing Board Wolfgang Burtscher attended Deputy Director-General responsible for Research Programmes within the Directorate-General for Research and Innovation Director responsible for Health systems, medical attended Andrzej Jan Rys products and innovation within the Directorate-General for Health and Food Safety Director responsible for Consumer, Environmental and Carlo Pettinelli apologies Health Technologies within the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Acting Director responsible for the Health Directorate Irene Norstedt attended within the Directorate-General for Research and Innovation - Head of Unit - Innovative and Personalised Medicine Alternate members attended Directorate-General for Research and Innovation attended Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs apologies the Directorate-General for Health and Food Safety

IMI2-GB-DEC-2019-01



Observers		
	=uropean Commission, DG RTD, Innovative and Personalised Medicine	apologies
	=uropean Commission, DG RTD, Innovative and Personalised Medicine	attended
	Scientific Research =uropean Commission, DG RTD, Innovative and Personalised Medicine	attended
	=uropean Commission, DG GROW, Biotechnology and Food Supply Chain	apologies
	substances of human origin =uropean Commission, DG SANTE, Medical products: quality, safety, innovation	apologies
	Johnson and Johnson	apologies
	UCB	confirmed
IMI2 JU		
Pierre Meulien	-xecutive Director	attended
		attended
		attended
1		attended



Annex III

Decision¹ taken at the 24th extraordinary meeting of the IMI2 Governing Board held on 12.12.2018

Title of the Decision of the Governing Board

Reference of the Decision

Decision of 12 December 2018 adopting the IMI2 JU Annual Work Plan and Budget for 2019, together with a revised Manual for submission, evaluation and grant award

[IMI2-GB-DEC-2018-32]

¹ To be made public on the basis of Article 9.7 of the Governing Board Rules of Procedure.